Twice-yearly depemokimab maintains exacerbation reduction and clinical remission over 2 years in patients with asthma, regardless of baseline asthma duration: SWIFT/AGILE integrated analysis
作者
Monica Kraft,Nizar N. Jarjour,Roland Buhl,Claire E. Tacon,David R. Muccino,Chang-Qing Zhu,David J. Jackson
出处
期刊:The European respiratory journal [European Respiratory Society] 日期:2026-09-05卷期号:: PA4790-PA4790
标识
DOI:10.1183/13993003.congress-2026.pa4790
摘要
Background: Depemokimab is the first ultra-long-acting biologic, with enhanced IL-5 binding affinity, high potency and extended half-life, enabling twice-yearly dosing. In the Phase III SWIFT-1/-2 studies, patients with type 2 (T2) asthma and shorter disease duration showed enhanced depemokimab response versus placebo over 1 year. Aims: Assess depemokimab’s efficacy over 2 years in the SWIFT-1/-2 and AGILE studies in patients with T2 asthma, split by asthma duration. Methods: Patients completing the randomised SWIFT-1/-2 studies could join the AGILE open-label extension study, where all patients received depemokimab, with follow-up up to 2 years (Figure). This post hoc analysis focused on patients receiving depemokimab for 2 years. Outcomes included annualised exacerbation rate (AER) and clinical remission (4- and 3-point definition; see Figure footnote) split by baseline asthma duration (<10, ≥10–<18, ≥18–<34, ≥34 years). Results: In total, 419 patients received 2 depemokimab doses in SWIFT-1/-2 and ≥1 dose in AGILE over a 2-year period. Patients maintained AER with depemokimab over 2 years regardless of asthma duration, with trends of lower exacerbation rates and higher rates of clinical remission observed in patients with baseline asthma duration <10 years compared with those with longer asthma duration (Figure). Conclusions: Twice-yearly depemokimab maintained efficacy over 2 years across asthma duration subgroups. Funding: GSK (SWIFT-1/-2: 206713/213744, NCT04719832 /NCT04718103; AGILE: 212895, NCT05243680 ) erj;68/suppl_70/PA4790/F1 F1 F1